» Articles » PMID: 32466887

Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients

Abstract

Background: Bleeding following percutaneous coronary intervention has important prognostic implications. The Academic Research Consortium (ARC) recently proposed a list of clinical criteria to define patients at high bleeding risk (HBR).

Objectives: This study sought to validate the ARC definition for HBR patients in a contemporary real-world cohort.

Methods: Patients undergoing coronary stenting between 2014 and 2017 at a tertiary-care center were defined as HBR if they met at least 1 major or 2 minor ARC-HBR criteria. To account for the presence of multiple criteria, patients were further stratified by the number of times they fulfilled the ARC-HBR definition. The primary endpoint was a composite of peri-procedural in-hospital or post-discharge bleeding at 1 year. Secondary endpoints included individual components of the primary bleeding endpoint, myocardial infarction, and all-cause mortality.

Results: Among 9,623 patients, 4,278 (44.4%) qualified as HBR. Moderate or severe anemia was the most common major criterion (33.2%); age ≥75 years was the most frequent minor criterion and the most common overall (46.8%). The rate of the primary bleeding endpoint at 1 year was 9.1% in HBR patients compared with 3.2% in non-HBR patients (p < 0.001), with a stepwise increase in bleeding risk corresponding to the number of times the ARC-HBR definition was fulfilled. HBR patients also experienced significantly higher rates of all secondary endpoints.

Conclusions: This study validates the ARC-HBR definition in a contemporary group of patients who underwent percutaneous coronary intervention. The ARC-HBR definition identified patients at increased risk not only for bleeding but also for thrombotic events, including all-cause mortality. Coexistence of multiple ARC-HBR criteria showed additive prognostic value.

Citing Articles

Safety Analysis of Spironolactone Use in Patients Undergoing Percutaneous Coronary Intervention with High Bleeding Risk: A Propensity Score-Matched Study.

Zhang J, Yan T, Liu R, Li Y, Zhou M, Wang H Cardiovasc Drugs Ther. 2025; .

PMID: 39907871 DOI: 10.1007/s10557-025-07676-3.


Development and Validation of a Nomogram for Predicting Long-Term Net Adverse Clinical Events in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention.

Zhang J, Chen Z, Liu R, Li Y, Zhao H, Li Y Rev Cardiovasc Med. 2025; 26(1):25352.

PMID: 39867174 PMC: 11760544. DOI: 10.31083/RCM25352.


Fragmented thrombi, targeted solutions: Exploring GPVI inhibition in high-shear environments.

Rabinowitz E, Bark D Biophys J. 2024; 124(1):6-7.

PMID: 39600092 PMC: 11739869. DOI: 10.1016/j.bpj.2024.11.3309.


Sex Differences in Patients Undergoing Left Main Stem Percutaneous Coronary Intervention for Stable Angina: Data From a National Registry.

Shamkhani W, Zathar Z, Khattak S, Nolan J, Chieffo A, Kinnaird T J Am Heart Assoc. 2024; 13(22):e036569.

PMID: 39547994 PMC: 11681398. DOI: 10.1161/JAHA.124.036569.


Validation of the Valve Academic Research Consortium High Bleeding Risk Definition in Patients Undergoing TAVR.

Avvedimento M, Cepas-Guillen P, Ternacle J, Urena M, Alperi A, Cheema A Circ Cardiovasc Interv. 2024; 18(1):e014800.

PMID: 39475194 PMC: 11748903. DOI: 10.1161/CIRCINTERVENTIONS.124.014800.